RxDoctor Payments Data

Efrain Antunez, MD

Internal Medicine · Miami, FLNPI 1326382169

Payments from drug & device makers

$2,507in general payments, 2019–2025

Across 43 payments — averaging $58.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Novo Nordisk$167
  • Johnson & Johnson$135
  • AbbVie$131
  • Redhill Biopharma Inc.$122
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$100
  • plus $316 from 7 others

What the payments were for

  • Food & beverage$1,007100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,507 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$6,813
Medicare patients
19
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$71,665
OzempicSemaglutide51$51,281
FarxigaDapagliflozin Propanediol36$30,422
JardianceEmpagliflozin49$29,670
RestasisCyclosporine28$21,539
JanuviaSitagliptin Phosphate32$21,005
TrulicityDulaglutide18$18,601
VascepaIcosapent Ethyl43$16,117
JanumetSitagliptin Phos/Metformin Hcl18$15,569
EntrestoSacubitril/Valsartan20$13,245
GemtesaVibegron27$12,657
SynjardyEmpagliflozin/Metformin Hcl17$10,217
BrilintaTicagrelor22$9,509
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$8,682
LinzessLinaclotide17$8,610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,537$71,665121 claims
Novo NordiskOzempic$167$51,28151 claims
AstraZenecaFarxiga, Brilinta, Symbicort$84$45,53185 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$15$45,32077 claims
AbbVieRestasis, Linzess, Lumigan, Synthroid$131$37,75789 claims
Lilly USA, LLCTrulicity$74$18,60118 claims
NovartisEntresto$18$13,24520 claims
Johnson & JohnsonInvokamet$135$7,96814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →